Proteomics and Mass Spectrometry: What Have We Learned About The Heart?

Author(s): Shaan Chugh, Colin Suen, Anthony Gramolini

Journal Name: Current Cardiology Reviews

Volume 6 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


The emergence of new platforms for the discovery of innovative therapeutics has provided a means for diagnosing cardiac disease in its early stages. Taking into consideration the global health burden of cardiac disease, clinicians require innovations in medical diagnostics that can be used for risk stratification. Proteomic based studies offer an avenue for the discovery of proteins that are differentially regulated during disease; such proteins could serve as novel biomarkers of the disease state. For instance, in clinical practice, the abundance of such biomarkers in blood could be correlated with the severity of the disease state. As such, early detection of biomarkers would enable an improvement in patient prognosis. In this review, we outline advancements in various proteomic platforms used to study the disease proteome and their applications to the field of clinical medicine. Specifically, we highlight the contributions of proteomicbased profiling experiments to the analysis of cardiovascular diseases.

Keywords: Proteomics, Mass Spectrometry, medical diagnostics, biomarkers, cardiovascular diseases

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [124 - 133]
Pages: 10
DOI: 10.2174/157340310791162631
Price: $65

Article Metrics

PDF: 14